FindTrial
Sign In

Role of gene repair in endometrial carcinomas

Mismatch repair protein status and hormone receptor expression in endometrial carcinoma: An Immunohistochemical study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/11/096861
Enrollment
25
Registered
2025-11-03
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N939- Abnormal uterine and vaginal bleeding, unspecified

Interventions

Intervention1: Nil: Nil

Sponsors

Maulana Azad Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed and histologically confirmed cases of Endometrial Carcinoma 2. More than 18 years of age

Exclusion criteria

Exclusion criteria: 1. Patients who have already received prior chemotherapy and radiotherapy

Design outcomes

Primary

MeasureTime frame
1. Proportion of cases with Mismatch Repair protein deficiency. 2. Proportion of cases with hormone receptor expression.Timepoint: Baseline—

Secondary

MeasureTime frame
1. Association of Endometrial carcinoma with Mismatch Repair protein deficiency with clinicopathological features including histological type, grade, stage, tumor infiltrating lymphocytes, type of invasive margin and lymphovascular invasion. 2.Association of Endometrial carcinoma expressing hormone receptors with clinicopathological features including histological type, grade, stage, tumor infiltrating lymphocytes, type of invasive margin and lymphovascular invasion. 3. Association of MSI status with hormone receptor expression. Timepoint: Baseline—

Countries

India

Contacts

Public ContactDr Nita Khurana

Maulana Azad Medical College

nitakhurana1@gmail.com9968604289

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026